BioWorld Today: ASCO Roundup- MacroGenics, Inc.

June 05, 2013 - MacroGenics, Inc.

MacroGenics Inc., of Rockville, Md., reported results from a Phase I study showing that margetuximab, an Fcmodified chimeric monoclonal antibody, was found to be tolerated at all doses tested in patients with advanced solid tumors expressing the HER2 oncoprotein. Antitumor activity was observed at all dose levels. At a dose of 0. 1 mg/kg once weekly, one patient experienced time to progression of 9.2 months. In addition, three patients experienced confirmed partial responses, including two with metastatic breast cancer lasting 3.3 months and 5.3 months. Four of 13 patients with gastroesophageal cancer experienced stable disease lasting a median of 3.6 months, with all but one previously failing anti-HER2 treatment.